Felipe Duran
Net worth: 68 351 $ as of 30/05/2026
Net worth: 68 351 $ as of 30/05/2026
Felipe Duran is currently Chief Financial Officer at iBio, Inc. since 2023.
Formerly, Mr. Duran was Chief Financial Officer-Lupin Latin America at Lupin Pharmaceuticals, Inc. from 2016 to 2021 and Manager-Financial Planning & Analysis at Noven Pharmaceuticals, Inc. Education includes undergraduate and MBA degrees from the University of Miami.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
IBIO, INC. 0.1% | 18/03/2026 | 35,974 ( 0.1% ) | 68 351 $ | 30/05/2026 |
| Companies | Position | Start |
|---|---|---|
| IBIO, INC. | Director of Finance/CFO | 12/02/2023 |
| Companies | Position | End |
|---|---|---|
Lupin Pharmaceuticals, Inc.
Lupin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes generic formulations, biotechnology products & APIs | Director of Finance/CFO | 30/04/2021 |
Noven Pharmaceuticals, Inc.
Noven Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research, development, manufacture, marketing and sale of transdermal pharmaceutical products | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 4 |
|---|---|
Noven Pharmaceuticals, Inc.
Noven Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research, development, manufacture, marketing and sale of transdermal pharmaceutical products | Commercial Services |
University of Miami
University of Miami Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
iBio, Inc.
iBio, Inc. Pharmaceuticals: OtherHealth Technology Engages in the development and commercialization of vaccines and therapeutic proteins | Health Technology |
Lupin Pharmaceuticals, Inc.
Lupin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes generic formulations, biotechnology products & APIs | Health Technology |
Select your edition
All financial news and data tailored to specific country editions